Another step backwards for Valneva
The group’s Covid vaccine, as well as Sanofi and Glaxosmithkline’s jab, might not reach Europe for some time.
Mitsubishi's Medicago heads for the Covid-19 booster queue
The Canadian subsidiary claims success in its pivotal trial, though capacity restraints will limit the jab’s role for now.
Bavarian Nordic goes it alone, for now
Phase 3 in RSV will begin without a partner, while decent Covid-19 booster data pave the way for pivotal development.
Biggest unpartnered assets: Argenx nears crunch time
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
Valneva scores a pyrrhic trial win
The group’s Covid-19 vaccine is on course for UK approval – but the UK doesn’t want it.
Valneva falls as UK contract axe falls
Valneva might have to look beyond the UK for vaccine sales after today's contract termination.
